Orexo and Janssen Pharmaceuticals, formerly Ortho-McNeil-Janssen Pharmaceuticals, and Janssen Pharmaceutica, have terminated their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs.
A third, undisclosed Janssen program was also terminated. Each party has regained all commercial rights for its respective drug discovery programs. The OX-CLI and OX-ESI programs, focusing on discovering and developing innovative new treatments for asthma, chronic obstructive pulmonary disease and other inflammatory diseases, will be closed.
